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Traditionally, the efficacy of an anticancer agent has been measured by response rate. With the development of biological molecular-
targeted agents, which have a different mechanism of action from conventional agents, it may be appropriate to consider alternative
criteria that reflect the positive effect of these biological agents on disease control, palliation, symptom improvement and quality of
life. One such targeted agent is the orally active epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839).
This article reviews the clinical experience of patients with advanced/metastatic non-small-cell lung cancer, who have received
gefitinib as part of a clinical trial or through the ‘Iressa’ Expanded Access Programme. Disease-control rates of B50% were observed
in some Expanded Access Programme series, comparable with results obtained from Phase II trials. Symptom improvement was also
reported. Information that will help identify those patients most likely to respond to treatment will become increasingly important.
Therefore, the possible role of prognostic markers and the relationship between epidermal growth factor receptor status and
response to gefitinib has been investigated. No clear association between epidermal growth factor receptor expression and response
was observed. Future studies of other biomarkers in the epidermal growth factor receptor pathway should help to identify which
patients are likely to benefit most from gefitinib.
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Patients with advanced/metastatic non-small-cell lung cancer
(NSCLC) have terminal disease. Therefore, treatment should aim
to improve palliation, quality of life and symptom improvement in
addition to prolonging survival. The benefits of biologically
targeted agents like gefitinib (‘Iressa’, ZD1839) are not always
evident from response rates, as their mechanism of action differs
from that of conventional cytotoxic chemotherapy agents. Assess-
ments of efficacy should take into account the overall benefit to the
patient, including disease control and effects on quality of life and
symptoms. In addition to efficacy data from clinical trials, data are
now available from the ‘Iressa’ Expanded Access Programme
(EAP). Some of these data are reviewed below.
Currently, there is much interest in the role of prognostic/
predictive factors and, in the future, these will become increasingly
important in targeting therapy to those patients who are most
likely to benefit. A range of baseline demographic factors and
potential predictive biological markers are under investigation in
patients receiving gefitinib, the significance of which remains to be
clarified.
CLINICAL BENEFIT WITH GEFITINIB
Unprecedented activity in NSCLC patients who have been
pretreated was demonstrated in Phase II gefitinib monotherapy
studies (‘Iressa’ Dose Evaluation in Advanced Lung cancer)
(IDEAL 1 and 2) (Fukuoka et al, 2003; Kris et al, 2003). Response
rates with gefitinib 250mgday
 1 were 18.4 and 11.8% in IDEAL 1
and 2, respectively. However, when disease control was considered
(objective response plus stable disease), it was evident that 54.4
and 42.2% of patients in IDEAL 1 and 2, respectively, experienced
clinical benefit. Furthermore, B40% of patients in each trial
experienced improvement in disease-related symptoms, assessed
using the Lung Cancer Subscale (LCS) of the Functional
Assessment of Cancer Therapy-Lung (FACT-L) questionnaire
(improvement rates at 250mgday
 1 were 40.3 and 43.1%,
respectively), which was associated with a longer overall survival
compared with patients without improvement (Douillard et al,
2002; Natale et al, 2002; Cella et al, 2003). These results emphasise
that, for a targeted agent like gefitinib, valuable clinical benefit can
be experienced by the patient that might not be reflected by the
response rate.
Similar results have been observed in the compassionate-use
setting, an example of which was presented at the American
Society of Clinical Oncology annual meeting 2003 (Lo ´pez Martin
et al, 2003), with updated results presented at the recent ‘Iressa’
Clinical Experience (ICE) meeting (Cortes-Funes, ICE abs).
Patients were included in the ‘Iressa’ EAP if they had experienced
progression of NSCLC after prior chemotherapy, were ineligible
for other gefitinib studies and had no alternative treatment
options. In this study, patients received treatment with oral
gefitinib 250mgday
 1 for at least 1 month, which was the
minimum time to evaluate efficacy. In addition to response rate,
disease control rate (defined as objective response plus stable
disease) and clinical benefit (defined in this analysis as an
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www.bjcancer.comimprovement in two principal variables, such as pain or Eastern
Cooperative Oncology Group performance status, or symptomatic
improvement, such as cough or haemoptysis, plus improvement in
one secondary variable, such as weight) were also recorded. Data
from 26 centres throughout Spain were analysed retrospectively.
The four major centres were Clinica Universitaria Navarra,
Hospital de Pontevedra, Hospital GTP Badalona and Hospital
Universitario 12 de Octubre.
Demographic characteristics of the 113 patients from this
Spanish series who fulfilled EAP criteria are given in Table 1. In
total, 96 patients were evaluable for response, with the remaining
17 patients being evaluable only for clinical benefit. Seven patients
(7.3%) had a partial response, examples of which are shown in
Figures 1A and B. Disease control was experienced by 44 (45.8%)
patients and disease control rates were similar, regardless of
histology, stage at diagnosis or previous chemotherapy. Addition-
ally, 23 out of 113 patients (20.4%) experienced symptom benefit
(evaluated retrospectively from patient charts). Clinical benefit, as
defined above, was observed in 59.2% of patients. Median time to
disease progression and median overall survival were 3.5 and 6.7
months, respectively (Figures 2A and B).
Drug-related adverse events recorded in this study were mainly
grade 1/2 (Table 2). There were four withdrawals, due to drug-
related adverse events (diarrhoea and fatigue in progressive
disease). It can be concluded from the Spanish experience that
gefitinib was well tolerated and showed antitumour activity in
these pretreated patients with advanced NSCLC, with a promising
rate of disease control and clinical benefit.
Efficacy data from the IDEAL trials were further supported by 20
large case series from the EAP (each with 425 patients) that were
presented at the ICE meeting (Mancuso, ICE abs; Haringhuizen,
ICE abs; Bendel, ICE abs; Gridelli (a and b), ICE abs; Bianco, ICE
abs; de Leeuw, ICE abs; Petersen, ICE abs; Reck, ICE abs; Soto
Parra (a–c), ICE abs; Cortes-Funes, ICE abs; Kowalczyk, ICE abs;
Chioni, ICE abs; Katz, ICE abs; Pallis, ICE abs; de Braud, ICE abs;
Razis, ICE abs; Boyer, ICE abs). Patients from these case series
were commonly heavily pretreated (Figure 3). For most case series,
response rates were o10%. In contrast, disease control was
experienced by many patients, with disease control rates of 5.7–
83% reported across the series (Figure 4). Some series described
evidence of symptom improvement. In all, 11 of the large case
series presented data on median survival (Figure 5), which ranged
Table 1 Spanish Expanded Access Programme experience – patient
demography
Patients fulfilling EAP in retrospective analysis (n) 113
Male/female (n) 89/24
Median age (range) (years) 61 (36–83)
ECOG performance status 0–1/2–3/4 (%) 73/26/1
Histology (%)
Adenocarcinoma 41.4
Squamous-cell carcinoma 39.6
Large-cell carcinoma 15.3
Other 3.6
Sites of measurable lesions (n)
Primary/lung 102
Nodes 44
Bone 25
Liver 15
Suprarenal 12
Central nervous system 10
Pleural 6
Adrenal 3
Other
a 4
No of sites
14 8
23 0
X33 5
Previous chemotherapy (n)
First line 24
Second line 55
Third line 34
aIncludes thoracic wall, supraclavicular, mediastinum and kidney. EAP¼Expanded
Access Programme; ECOG¼Eastern Cooperative Oncology Group.
Figure 1 Scans showing partial response in (A) second- and (B) third-line adenocarcinoma.
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also reported a 1-year survival of 31% (Kowalczyk, ICE abs).
There were several presentations at the 10th World Conference
on Lung Cancer (WCLC) that reported data from the compassio-
nate-use setting (Gips et al, 2003; Haringhuizen et al, 2003; Janne
et al, 2003; Park et al, 2003; Soto Parra et al, 2003). Response rates
with gefitinib were varied, but most reports described disease
control rates of 440%, comparable with data from the Phase II
IDEAL trials. Furthermore, 1-year survival rates of 29% (Har-
inghuizen et al, 2003; Janne et al, 2003) and 48.7% (Park et al,
2003) were reported.
Relationship between disease control and survival/
symptom improvement
In IDEAL 2, median overall survival in the subset of patients
surviving for 48 weeks was greater for patients with partial
response (16.3 months) or stable disease (9.4 months) than for
those with progressive disease (5.4 months) (Cella et al, 2003). A
similar association was noted in two of the large case series from
the ICE meeting that evaluated survival by disease control (Soto
Parra (a and b), ICE abs). In the first, median survival was longer
for patients with disease control (6 months) compared to that for
all patients (4 months). In the second, median survival was 5
months for those with stable disease compared to 2.5 months for
patients with progressive disease, and was 3 months overall. This
study also reported a corresponding difference in 1-year survival
(28% for those with stable disease vs 22% overall).
A correlation between symptom improvement and tumour
response was observed for IDEAL 2, such that most patients with a
tumour response or stable disease had symptom improvement
(Cella et al, 2003). Four of the large case series at the ICE meeting
had information on symptom-improvement rates, which ranged
from 19–39% (Haringhuizen, ICE abs; Petersen, ICE abs;
Kowalczyk, ICE abs; Pallis, ICE abs). In addition to an overall
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Figure 2 (A) Time to progression and (B) overall survival for the 113
evaluable patients from the Spanish case series.
Table 2 Spanish Expanded Access Programme experience – most
common drug-related adverse events (in X5% of patients, n¼113)
Grade 1/2 Grade 3/4
Skin disorders, n (%) 48 (42.5) 4 (3.5)
Asthenia, n (%) 23 (20.4) 6 (5.3)
Gastrointestinal disorders, n (%)
Diarrhoea 24 (21.2) 1 (0.9)
Anorexia 11 (9.7) 4 (3.5)
Nausea/vomiting 12 (0.6) 1 (0.9)
Neurological,
a n (%) 11 (9.7) 2 (1.8)
Alteration to central nervous and
peripheral systems,
a n (%)
5 (4.4) 1 (0.9)
aMainly disease related or related to previous chemotherapy.
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Figure 3 Previous chemotherapy in large case series presented at the
‘Iressa’ Clinical Experience meeting.
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Figure 4 Disease control in large case series presented at the ‘Iressa’
Clinical Experience meeting.
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patients with disease control had symptom improvement.
PROGNOSTIC MARKERS AND EPIDERMAL GROWTH
FACTOR RECEPTOR STATUS
The identification of prognostic and predictive factors is important
because it should help to determine which patients will benefit
most from therapy. There are a number of biological markers
involved in cell signalling pathways, including epidermal growth
factor receptor (EGFR), p27 and Ki67, that might have potential as
prognostic/predictive markers (Fu et al, 1999; Arteaga, 2002).
Although EGFR is commonly expressed in NSCLC and other
tumours, its role as a prognostic factor is not well defined and
conflicting results have been reported (Nicholson et al, 2001). This
may, in part, be due to the lack of a standard validated method for
assessing EGFR expression, which makes it difficult to compare
results from different studies (Arteaga, 2002). It is not known
whether the level of EGFR expression is predictive of response to
EGFR-targeted therapy. Recent data on the relationship between
EGFR expression levels and the response to gefitinib are now
available from the Phase II IDEAL trials and the EAP.
An exploratory analysis of EGFR expression in tumour biopsies
has recently been performed by immunohistochemistry in the
IDEAL 1 and 2 trials, in which formalin-fixed, paraffin-embedded
sections were stained with the 2-18C9 clone antibody. Four levels
of staining intensity were recorded: none (0), weak (1þ),
moderate (2þ) or strong (3þ). This method of visual scoring
of immunohistochemical stains for EGFR by experienced ob-
servers, using a simple and objective scoring system, was shown to
be highly reproducible (Janas et al, 2003). Patients evaluable for
EGFR status plus either objective response or symptom improve-
ment were assessed. There was no evidence for a consistent
relationship between EGFR expression levels and response (Bailey
et al, 2003). Patients with low and high levels of EGFR responded
to gefitinib. There was a tendency towards a positive correlation
between symptom improvement and strong (3þ) EGFR mem-
brane staining, but some patients with symptom improvement had
samples without strong staining. Therefore, it would be clinically
unacceptable to select patients for gefitinib treatment on the basis
of strong EGFR staining.
An Italian case series from the EAP aimed to evaluate the role of
EGFR detection on prediction of response or disease control in
patients treated with gefitinib. Results from 50 evaluable patients
were presented recently at the WCLC (Soto Parra et al, 2003),
updated from data presented at the ICE meeting (Soto Parra (c),
ICE abs). Consistent with the studies described above, response
rate was 10% (one complete and four partial responses) and 50%
of patients experienced disease control with a median duration of 6
months.
Immunohistochemistry was used to analyse EGFR membrane
immunoreactivity, which was classified according to staining
intensity (negative/faint (0/1þ) or medium/strong (2þ/3þ))
(Figure 6) and percentage of immunoreactive (IR) cells (negative/
low expressors (0–19% IR) or high expressors (X20% IR)). In this
exploratory analysis, there was no significant correlation between
response to gefitinib and EGFR staining intensity (P¼0.1) or
between disease control and EGFR staining intensity (P¼0.39)
(Table 3), in agreement with the results of Bailey et al (2003).
In a selection of other cases from the EAP, variable results were
observed: some responders were negative for EGFR (Gridelli (b),
ICE abs) and others had positive staining for EGFR in X20% of
cells (de Braud, ICE abs). These results again suggest the lack of a
clear association between EGFR status and response to gefitinib.
The IDEAL trials also provided some information on demo-
graphic prognostic factors. In IDEAL 1, prognostic factors
associated with an objective response according to multivariate
analysis included performance status (0/1 vs 2), female gender and
adenocarcinoma histology (vs other histologies) (Fukuoka et al,
2003).
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Figure 5 Median survival in large case series with data available at the
‘Iressa’ Clinical Experience meeting.
Figure 6 Example of staining intensity.
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chemotherapy in previously untreated patients with NSCLC
(INTACT (‘Iressa’ NSCLC Trial Assessing Combination Treat-
ment) 1 and 2) also included analysis of possible prognostic factors
(Giaccone et al, 2003; Herbst et al, 2003). Multivariate analysis
showed that performance status 2, weight loss, bone/liver
metastases, squamous cell, large cell or unspecified histology were
all significant for worse survival in both trials, as were male gender
and brain metastases in INTACT 2. Multivariate analysis of
INTACT data did not show any consistent or demonstrable effects
of gefitinib in combination with chemotherapy, compared with
chemotherapy alone, on known prognostic factors for survival
outcome.
Another possibility for response prediction currently being
evaluated is the use of a high-throughput reverse transcriptase–
polymerase chain reaction assay, to determine a correlation
between quantitative gene expression in the tumour and response
to gefitinib monotherapy in patients with NSCLC (Natale et al,
2003). Of 192 genes profiled in 17 patients, expression of several
genes (including STAT5A, STAT5B and g-catenin) correlated with
clinical response. Further studies in a larger cohort of patients are
necessary to further elucidate the significance of these genes and
other candidate markers of response.
DISCUSSION
It is clear from clinical trials that patients can experience clinical
benefit from gefitinib that is not necessarily reflected in the
objective response rate and so other factors, such as disease
control and symptom improvement, should be taken into
consideration when evaluating such targeted agents. Large case
series from the EAP have been presented at international
congresses and at the ICE meeting, and support the idea that
patients can still experience benefit despite low response rates.
Some studies suggested that disease control was related to
improved survival. These data indicate that gefitinib is a promising
therapy for patients with advanced NSCLC, who have few
treatment options.
Another important feature of targeted therapy is the potential
ability to predict response to therapy. For EGFR-targeted agents
such as gefitinib, it is of interest to determine any relationship
between EGFR expression levels and response, with a view to being
able to select for treatment those patients who are most likely to
benefit. However, it appears that there is no consistent relationship
between EGFR status and response to gefitinib.
There do seem to be some patterns emerging with respect to
prognostic factors, with characteristics of performance status,
gender and histology influencing survival, although responses were
observed in all groups. In some studies, symptom improvement
has been associated with improved survival (Cella et al, 2003).
Future studies of other biomarkers in the EGFR pathway should
help identify which patients are likely to benefit most from
gefitinib, and extensive investigations are underway to help clarify
the mechanisms of action and resistance. Tissue collection will be
performed across gefitinib trials and genomic/proteomic colla-
borative exploratory studies are ongoing.
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